COVID-19 Monoclonal Antibodies: Key Issues After Emergency Use Authorization

COVID-19 mAbs: Key Issues After EUA

White Paper

COVID-19 Monoclonal Antibodies: Key Issues After Emergency Use Authorization

Published date

November 16, 2020

Duke-Margolis Affiliated Authors

morgan romine

Morgan Romine, MPA

Chief of Staff
Senior Team Member

Marta Wosinska

Marta WosiƄska, PhD

Consulting Professor, Fuqua School of Business
Deputy Director, Policy, Duke-Margolis Center for Health Policy
Margolis Core Faculty

Photo of Hemi Tewarson

Hemi Tewarson

Visiting Senior Policy Fellow

MHL

Marianne Hamilton Lopez, PhD, MPA

Research Director, Value-Based Payment Reform
Adjunct Associate Professor
Senior Team Member
Margolis Core Faculty

Kroetsch

Adam Kroetsch, MPP

Research Director, Biomedical Innovation and Regulatory Policy
Senior Team Member

nitzan arad

Nitzan Arad

Research Associate

Nick Fiore

Nick Fiore

Senior Research Assistant

Photo of Anna Zavodszky

Anna Zavodszky

Research Assistant

Mark McClellan

Mark McClellan, MD, PhD

Director of Margolis Center
Robert J. Margolis, MD, Professor of Business, Medicine and Policy
Margolis Executive Core Faculty